Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Severe Eosinophilic Asthma

- PMLiVE

GSK shares positive phase 3 results for long-acting biologic in severe asthma

Depemokimab is designed to allow for six-month dosing intervals for patients with the lung condition

- PMLiVE

GSK’s long-acting biologic shown to reduce severe asthma attacks in phase 3 studies

Approximately 200,000 people in the UK have severe cases of the lung condition

- PMLiVE

New syndicated report – Living with Ulcerative Colitis 2024

Living with Ulcerative Colitis (UC) is a new syndicated patient report that presents valuable insights into the unmet needs and the burden experienced by patients living with UC. The report...

Inizio

- PMLiVE

New syndicated COPD report now available

Living with COPD 2023

Inizio

New syndicated reports now available

Living with CD, PsO, IPF & PF-ILD 2023

Inizio

- PMLiVE

AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma

An estimated 98,000 patients with severe uncontrolled asthma may be eligible for the new treatment

Infographic: Living with: The journey from the patient’s perspective

View our re-vamped interactive infographic to unlock key insights from various Living With reports

Inizio

- PMLiVE

AstraZeneca’s severe asthma treatment approved in EU for self-administration

Most healthcare providers, patients and caregivers are able to successfully use the pre-filled pen

- PMLiVE

AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma

Tezspire demonstrated reduced annualised rate of asthma exacerbations

- PMLiVE

AstraZeneca’s Tezspire receives EC approval as severe asthma add-on treatment

Tezspire demonstrated superiority across every primary and key secondary endpoint compared to placebo

New syndicated patient reports –

Living with Uterine Fibroids and Endometriosis US 2022

Inizio

Animation: Living With

The journey from the patient's perspective

Inizio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links